World Market for Anti-Infectives (Antifungals, Antibacterials and Antivirals)

This research report on Anti-Infectives focuses on three key segments of treatment:

• Antifungals (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)
• Antibacterials (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)
• Antivirals (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals)

The report covers both currently marketed and late stage development products. Revenues for each segment were generated using dollar and unit sales for each product.

A novel approach in this report is that it provides revenue by product type but also the 'market' for treatments by type of infection, enabling marketers to research the best markets where a variety of products may be implemented.

The report includes statistical information for infections by type worldwide, with special emphasis on the U.S. and Europe. The market segments provide an overview, description of products on the market, description of products in development, market estimates and forecasts, and competitive analysis of leading providers.

The area of anti-infectives represents an exciting frontier for development of potential life-saving products. However, there are a number of issues and trends that have a direct influence on this market and manufacturers' ability to successfully operate in the market. The issues and trends affecting this market include:

• Drug Resistance
  
• HIV Trends, Cost, and Access to Drug Therapy
  
• Other Immunocompromised Population Issues
  
• Alliances and Partnerships
  
• New Developments
  
• Rx-to-OTC Switches
  

The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals focused on the anti-infective industry. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study Kalorama Information conducted interviews with key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Specific interviews with pharmaceutical company representatives included marketing directors, division managers, and product representatives.

All market data pertains to the world market at the manufacturers' level. The base year for data was 2011. Historical data was provided for the years 2007 through 2010, with forecast data provided for 2012 through 2015. Compound annual growth rates (CAGRs) are provided for the 2007-2011, 2011-2015 and 2007-2015 periods for each industry segment covered. Competitive analysis is provided for the years 2007 through 2011 with a special focus on 2011. The forecasted market analysis for 2011-2015 was based on probability of approval and sales of products in late stage development, future trends in current product demand, generic penetration, product marketing, and relevant demographic trends.

Companies profiled in this report include:

• Abbott Laboratories
  
• Astellas
  
• AstraZeneca
  
• Bayer
  
• Bristol-Myers Squibb
  
• Cubist
  
• Daiichi Sankyo
  
• Gilead Sciences
  
• GlaxoSmithKline
  
• Johnson & Johnson
  
• Merck
  
• Novartis
  
• Pfizer
  
• Roche
  

Additional Information

Gilead Leads Antiviral Therapy Sales: Kalorama

With combined sales from the top HIV treatment on the market and several other drugs, Gilead Sciences leads the antiviral market, according to healthcare market research publisher Kalorama Information, closely followed by Bristol-Myers Squibb, Roche and Merck. Led by growth in antivirals, the market for all anti-infectives reached $53 billion in 2011, according to this new report by Kalorama Information.

Atripla is the company's newest antiviral product, launched in July 2006, and it's the leading treatment for HIV. It is a nucleoside analog, part of a highly active antiretroviral therapy (HAART) regimen or "cocktail" that under best conditions can reduce the presence of HIV RNA in the patient's plasma to undetectable levels, thus prolonging survival. Kalorama estimated the product's sales to be $3.2 billion in 2011. Truvada, Viread, Hepsera are the company's other antiviral drugs. However, the report finds this is a highly competitive market and other brands are competing for market leadership.

"Gilead Sciences will likely remain strong in the market, but other companies are gaining," said Melissa Elder, the report's author. "Baraclude, for instance, has quadrupled in revenues in the past four years."

Bristol-Myers Squibb holds second place in the antiviral drug market, according to Kalorama Information. The company's Baraclude nucleoside analog has grown from $257 million in sales in 2007 to $1.1 billion today. The company's other leading antiviral drugs are Sustiva and Reyataz. Roche holds the third market position overall; the company's key antivirals include Pegasys, Valcyte, and Tamiflu.

GlaxoSmithKline alone accounted for 25% of the antiviral market in 2009, but has since declined due to patent expirations on key products. The company is not inactive, however. In November 2009, GlaxoSmithKline and Pfizer launched ViiV Healthcare, a new company focusing on HIV treatment that combines the strength of both companies' product and development pipelines in the HIV treatment area. For 2011, the new company accounted for one tenth of the antiviral drug market, according to Kalorama.

Of all the anti-infective drug markets that Kalorama has researched in its report, antivirals presented the most growth and competitive activity. This trend is expected to continue for 2011 with half year sales for key products already showing similar increases. This Kalorama report contains more segment market estimates, estimates for revenues by infection treated, and profiles of key companies in the market.

CHAPTER ONE: EXECUTIVE SUMMARY
Introduction
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Overview
Introduction to Pathogens
Demographics of the World
Life Expectancy
Infections and Drug Resistance
Causes of Drug Resistance
Drug Resistance in Select Populations
Measures for Reducing Resistance
HIV Trends
Manufacturer and Marketer Trends
Trends in Partnerships and Alliances
Developers Trends
Aradigm
ARD-3100
Phase II
Cystic fibrosis
ARD-3150
Phase II
Bronchiectasis
ARD-1100
Preclinical
Inhalation anthrax
Trends in Rx-to-OTC Switches

CHAPTER THREE: ANTIFUNGAL DRUGS
Overview
Types of Fungal Infections
Superficial
Systemic
General Fungal Infection Statistics
Fungal Infection Risk
Description of Antifungal Products
Systemic Antifungals
Topical Antifungals
Market Overview
Total Market Size and Forecast
Antifungal Market by Product Type
Antifungal Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products

CHAPTER FOUR: ANTIBACTERIAL DRUGS
Overview
Classification of Antibacterial Organisms
Antimicrobial Spectrum
Bacterial Resistance
Principles of Anti-bacterial Therapy
Combination Therapy and Prophylactic Use
Bacterial Infection Statistics
Bacterial Infection Risk
Classifications of Antibacterial Products
Aminoglycosides
Carbapenems
Cephalosporins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Market Overview
Total Market Size and Forecast
Antibacterial Market by Product Type
Antibacterial Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products

CHAPTER FIVE: ANTIVIRAL DRUGS
Overview: Introduction to Viruses
Examples of Pathogenic Viruses
Virus Function and Life History
Replication in DNA Viruses
Replication of RNA Viruses
Replication in Retroviruses
Host Defenses Against Viruses 8
Viral Ploys to Invade Host Cells and Circumvent Host Responses
Invasion of Host Cells
Subversion of the Immune Response
Avoidance of Immune Detection and Attack by Killer Cells
HIV and AIDS
Viral Infection Statistics
Description of Antivirals Products
Nucleoside Analogs, Transcriptase Inhibitors and DNA Polymerase Inhibitors
Protease Inhibitors
Other Antivirals
Market Overview
Total Market Size and Forecast
Antiviral Market by Product Type
Antiviral Market by Geographical Region
Market Analysis by Treated Condition
Competitive Analysis
Leading Products

CHAPTER SIX: MARKET SUMMARY
Market by Product Segment (Antifungals, Antibacterials, Antivirals)

CHAPTER SEVEN: CORPORATE PROFILES
Introduction
Abbott Laboratories
Astellas
AstraZeneca
Bayer Healthcare Pharmaceuticals (Bayer Schering Pharma)
Bristol-Myers Squibb
Cubist
Daiichi Sankyo
Gilead Sciences
GlaxoSmithKline
Johnson & Johnson
Merck
Novartis
Pfizer
Roche

APPENDIX: COMPANY DIRECTORY

TABLE OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

Table 1-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 1-1: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 1-2: World Market for Anti-Infectives Estimated Market Share of Leading Suppliers, 2011

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Table 2-1: World Population by Selected Geographical Region, 2010 - 2050

Table 2-2: Average Life Expectancy in Years by Country 1980, 2004 and 2009

Figure 2-2: Average Life Expectancy in Years by Country 1980 and 2009

Table 2-3: Worldwide HIV/AIDS Infections

Table 2-4: Women Living with HIV/AIDS, by Region 2001 to 2009, Number

Table 2-5: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income Countries, 2009 based on 2010 WHO Guidelines

Table 2-6: Antiretroviral Access for HIV Infected Individuals in Low- and Middle-Income
Countries, by Selected Countries, 2009 based on 2010 WHO Guidelines

Table 2-7: Anti-Infective Drugs in Development by Developer

Table 2-8: Anti-infectives Ingredients Transferred from Rx-to-OTC Status

Figure 2-3: Anti-infectives Ingredients Transferred from Rx-to-OTC by Year

CHAPTER THREE: ANTIFUNGAL DRUGS

Table 3-1: Incidence of Infections by Type, 2010

Figure 3-1: Incidence of Infections by Type, 2010

Table 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 3-2: World Population at Risk for Fungal Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 3-3: Treatment Options for Fungal Infections , (Type, Brand, and Manufacturer)

Table 3-4: The World Market for Antifungal Drugs 2007-2015

Figure 3-3: The World Market for Antifungal Drugs 2007-2015

Table 3-5: Antifungal Drug Market by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-4: The World Market for Antifungal Drugs Revenues by Type 2007-2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Figure 3-5: The World Market for Antifungal Drugs Revenues by Type 2011 and 2015 , (Allylamines, Azoles, Polyene Macrolides, Other Antifungals)

Table 3-6: The World Market for Antifungal Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 3-6: The World Market for Antifungal Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 3-7: World Antifungal Market Estimated Products Sales by Infection Type , (Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Figure 3-7: World Antifungal Market Estimated Distribution of Products Sales by Infection Type, 2011 Candida Infections, Seborrheic Dermatitis, Onychomycosis, Other Infections)

Table 3-8: World Market for Antifungal Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 3-8: World Market for Antifungal Drugs Estimated Revenues of Leading Suppliers, 5-year Comparison 2007-2011

Figure 3-9: World Market for Antifungal Drugs Estimated Market Share of Leading Suppliers, 2011

Table 3-9: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

Figure 3-10: World Market for Antifungal Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FOUR: ANTIBACTERIAL DRUGS

Table 4-1: Antibiotics with Difficult Penetration

Table 4-2: Estimated World and U.S. Incidence of Bacterial Infections, 2010

Figure 4-1: Estimated World and U.S. Incidence of Bacterial Infections

Table 4-3: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Figure 4-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010

Table 4-4: Treatment Options for Bacterial Infections , (Type, Brand, and Manufacturer)

Table 4-5: The World Market for Antibacterial Drugs 2007-2015

Figure 4-3: The World Market for Antibacterial Drugs 2007-2015

Table 4-6: Antibacterial Drug Market by Type 2007-2015

Figure 4-4: The World Market for Antibacterial Drugs Revenues by Type, 2007-2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Figure 4-5: The World Market for Antibacterial Drugs Revenues by Type 2011 and 2015 , (Aminoglycosides, Carbapenems, Cephalosporins, Macrolides, Penicillins, Quinolones, Sulfonamides, Tetracyclines, Others)

Table 4-7: The World Market for Antibacterial Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 4-6: The World Market for Antibacterial Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 4-8: World Antibacterial Market Estimated Products Sales by Infection Type , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Figure 4-7: World Antibacterial Market Estimated Distribution of Products Sales by Infection Type, 2011 , (Upper and Lower Respiratory Tract Infections, Ear, Sinus Infections, Skin & Skin Structure Infections Gynecological Infections; Sexually Transmitted Infections, Urinary Tract Infections, Abdominal Infections, Other Infections)

Table 4-9: World Market for Antibacterial Drugs Estimated Revenues and Market Share of Leading Suppliers 2007-2011

Figure 4-8: World Market for Antibacterial Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 4-9: World Market for Antibacterial Drugs Estimated Market Share of Leading Suppliers, 2011

Table 4-10: World Market for Antibacterial Drugs Estimated Sales of Select Products 2007-2011

CHAPTER FIVE: ANTIVIRAL DRUGS

Table 5-1: Host Cell Receptors

Table 5-2: Estimated World and U.S. Incidence of Viral Infections, 2010

Figure 5-1: Estimated World and U.S. Incidence of Leading Viral Infections

Table 5-3: Treatment Options for Viral Infections , (Type, Brand, and Manufacturer)

Table 5-4: The World Market for Antiviral Drugs 2007-2015

Figure 5-2: The World Market for Antiviral Drugs 2007-2015

Table 5-5: Antiviral Drug Market by Type 2007-2015

Figure 5-3: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2007-2015

Figure 5-4: The World Market for Antiviral Drugs Revenues by Type , (Nucleoside Analogs, Transcriptase Inhibitors, DNA Polymerase Inhibitors, Protease Inhibitors, Other Antivirals) 2011 and 2015

Table 5-6: The World Market for Antiviral Drugs Estimated Products Sales by Geographic Region 2007-2015

Figure 5-5: The World Market for Antiviral Drugs Estimated Product Sales by Geographic Region 2007-2015

Table 5-7: World Antiviral Market Estimated Products Sales by Infection Type (HIV, Hepatitis, Other Infections, Total)

Figure 5-6: World Antiviral Market Estimated Distribution of Products Sales by Infection Type, 2011 (HIV, Hepatitis, Other Infections, Total)

Table 5-8: World Market for Antiviral Drugs Estimated Revenues and Market Share of Leading Suppliers 2006-2009

Figure 5-7: World Market for Antiviral Drugs Estimated Revenues of Leading Suppliers 2007-2011

Figure 5-8: World Market for Antiviral Drugs Estimated Market Share of Leading Suppliers, 2011

Table 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

Figure 5-9: World Market for Antiviral Drugs Estimated Sales of Top Products 2007-2011

CHAPTER SIX: MARKET SUMMARY

Table 6-1: The Global Market for Anti-Infectives by Product Segment, 2007-2015

Figure 6-1: The World Market for Anti-Infective Drugs 2007-2015

Figure 6-2: The Global Market for Anti-Infectives by Product Segment, 2011

Figure 6-3: The Global Market for Anti-Infectives by Product Segment, 2015